CARVEDILOL PLUS NUCS TO PREVENT THE PROGRESSION OF ESOPHAGEAL VARICES IN VIROLOGICAL SUPPRESSED HBV-CIRRHOSIS PATIENTS: A RANDOMISED, OPEN-LABEL TRIAL

被引：0

作者：

Wang, Bingqiong ^{[1
]}

Zhou, Jialing ^{[1
]}

Wu, Xiaoning ^{[2
]}

Sun, Yameng ^{[2
]}

Li, Lei ^{[3
]}

Li, Ping ^{[4
]}

Li, Minghui ^{[5
]}

Jiang, Wei ^{[6
]}

Xu, Mingyi ^{[7
]}

Feng, Bo ^{[8
]}

Xu, Xiaoyuan ^{[9
]}

Cheng, Jilin ^{[10
]}

Xie, Wen ^{[11
]}

Han, Tao ^{[12
]}

Wang, Xiaozhong ^{[13
]}

Li, Hai ^{[14
]}

Piao, Hongxin ^{[15
]}

Zhao, Xinyu ^{[16
,17
,18
]}

Chen, Shuyan ^{[5
]}

Meng, Tongtong ^{[2
]}

Guan, Qiushuang ^{[1
]}

Meng, Fandong ^{[19
]}

Kong, Yuanyuan ^{[20
,21
]}

Ou, Xiaojuan ^{[2
]}

Jia, Jidong ^{[2
]}

You, Hong ^{[5
]}

机构：

[1] Capital Med Univ, Beijing Key Lab Translat Med Liver Cirrhosis, Natl Clin Res Ctr Digest Dis, Liver Res Ctr,Beijing Friendship Hosp, Beijing, Peoples R China

[2] Capital Med Univ, Beijing Friendship Hosp, Natl Clin Res Ctr Digest Dis, Liver Res Ctr, Beijing, Peoples R China

[3] Capital Med Univ, Beijing Youan Hosp, Dept Gastroenterol & Hepatol, Beijing, Peoples R China

[4] Tianjin Second Peoples Hosp, Dept Hepatol, Tianjin, Peoples R China

[5] Capital Med Univ, Beijing Friendship Hosp, Liver Res Ctr, Beijing, Peoples R China

[6] Fudan Univ, Dept Gastroenterol, Zhongshan Hosp Xiamen, Xiamen 361015, Peoples R China

[7] Shanghai Jiao Tong Univ, Sch Med, Dept Gastroenterol & Hepatol, Shanghai Gen Hosp, Shanghai, Peoples R China

[8] Peking Univ, Peoples Hosp, Beijing, Peoples R China

[9] Peking Univ First Hosp, Beijing, Peoples R China

[10] Shanghai Publ Hlth Clin Ctr, Dept Gastroenterol, Shanghai, Peoples R China

[11] Capital Med Univ, Beijing Ditan Hosp, Ctr Liver Dis, Beijing, Peoples R China

[12] Tianjin Med Univ, Dept Hepatol, Tianjin Cent Hosp 3, Tianjin, Peoples R China

[13] Xinjiang Med Univ, Xinjiang Hosp Tradit Chinese Med, Affiliated Hosp 4, Urumqi, Xinjiang, Peoples R China

[14] Tianjin Xiqing Hosp, Dept Gastroenterol, Tianjin, Peoples R China

[15] Yanbian Univ, Dept Infect Dis, Affiliated Hosp, Yanji, Jilin, Peoples R China

[16] Natl Clin Res Ctr Digest Dis, Dept Clin Epidemiol, Beijing, Peoples R China

[17] Natl Clin Res Ctr Digest Dis, EBM Unit, Beijing, Peoples R China

[18] Capital Med Univ, Beijing Friendship Hosp, Beijing, Peoples R China

[19] Capital Med Univ, Beijing Friendship Hosp, Natl Clin Res Ctr Digest Dis, Dept Gastroenterol, Beijing, Peoples R China

[20] Capital Med Univ, Beijing Friendship Hosp, Beijing Clin Res Inst, Clin Epidemiol, Beijing, Peoples R China

[21] Capital Med Univ, Beijing Friendship Hosp, Beijing Clin Res Inst, EBM Unit, Beijing, Peoples R China

来源：

HEPATOLOGY | 2023年 / 78卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

206

引用

页码：S217 / S218

页数：2

共 50 条

[41] Health-related quality of life in older patients with HER plus metastatic breast cancer: Comparing pertuzumab plus trastuzumab with or without metronomic chemotherapy in a randomised open-label phase II clinical trial
Dal Lago, Lissandra
Uwimana, Aime Lambert
Coens, Corneel
Vuylsteke, Peter
Curigliano, Giuseppe
Brouwers, Barbara
Jagiello-Gruszfeld, Agnieszka
Altintas, Sevilay
Tryfonidis, Konstantinos
Poncet, Coralie
Bottomley, Andrew
Sousa, Berta
Brain, Etienne
Wildiers, Hans
JOURNAL OF GERIATRIC ONCOLOGY, 2022, 13 (05) : 582 - 593
[42] Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial
Yamada, Yasuhide
Takahari, Daisuke
Matsumoto, Hiroshi
Baba, Hideo
Nakamura, Masato
Yoshida, Kazuhiro
Yoshida, Motoki
Iwamoto, Shigeyoshi
Shimada, Ken
Komatsu, Yoshito
Sasaki, Yasutsuna
Satoh, Taroh
Takahashi, Keiichi
Mishima, Hideyuki
Muro, Kei
Watanabe, Masahiko
Sakata, Yuh
Morita, Satoshi
Shimada, Yasuhiro
Sugihara, Kenichi
LANCET ONCOLOGY, 2013, 14 (13): : 1278 - 1286
[43] Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial
Hegewisch-Becker, Susanna
Graeven, Ullrich
Lerchenmueller, Christian A.
Killing, Birgitta
Depenbusch, Reinhard
Steffens, Claus-Christoph
Al-Batran, Salah-Eddin
Lange, Thoralf
Dietrich, Georg
Stoehlmacher, Jan
Tannapfel, Andrea
Reinacher-Schick, Anke
Quidde, Julia
Trarbach, Tanja
Hinke, Axel
Schmoll, Hans-Joachim
Arnold, Dirk
LANCET ONCOLOGY, 2015, 16 (13): : 1355 - 1369
[44] Busulfan plus cyclophosphamide versus busulfan plus fludarabine as a preparative regimen for allogeneic haemopoietic stem-cell transplantation in patients with acute myeloid leukaemia: an open-label, multicentre, randomised, phase 3 trial
Rambaldi, Alessandro
Grassi, Anna
Masciulli, Arianna
Boschini, Cristina
Mico, Maria Caterina
Busca, Alessandro
Bruno, Benedetto
Cavattoni, Irene
Santarone, Stella
Raimondi, Roberto
Montanari, Mauro
Milone, Giuseppe
Chiusolo, Patrizia
Pastore, Domenico
Guidi, Stefano
Patriarca, Francesca
Risitano, Antonio M.
Saporiti, Giorgia
Pini, Massimo
Terruzzi, Elisabetta
Arcese, William
Marotta, Giuseppe
Carella, Angelo Michele
Nagler, Arnon
Russo, Domenico
Corradini, Paolo
Alessandrino, Emilio Paolo
Torelli, Giovanni Fernando
Scime, Rosanna
Mordini, Nicola
Oldani, Elena
Marfisi, Rosa Maria
Bacigalupo, Andrea
Bosi, Alberto
LANCET ONCOLOGY, 2015, 16 (15): : 1525 - 1536
[45] Radiotherapy plus camrelizumab and irinotecan for oligometastatic esophageal squamous cell carcinoma patients after first-line immunotherapy plus chemotherapy failure: An open-label, single-arm, phase II trial
Zhao, Wensi
Ke, Shaobo
Cai, Xiaojun
Zuo, Zhigang
Shi, Wei
Qiu, Hu
Cai, Gaoke
Gong, Yi
Wu, Yong
Ruan, Shasha
Chen, Yongshun
RADIOTHERAPY AND ONCOLOGY, 2023, 184
[46] Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trial
Sacco, Assuntina G.
Chen, Ruifeng
Worden, Francis P.
Wong, Deborah J. L.
Adkins, Douglas
Swiecicki, Paul
Chai-Ho, Wanxing
Oppelt, Peter
Ghosh, Debanjali
Bykowski, Julie
Molinolo, Alfredo
Pittman, Emily
Estrada, M. Valeria
Gold, Kathryn
Daniels, Gregory
Lippman, Scott M.
Natsuhara, Amanda
Messer, Karen
Cohen, Ezra E. W.
LANCET ONCOLOGY, 2021, 22 (06): : 883 - 892
[47] Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial
Pignata, Sandro
Scambia, Giovanni
Katsaros, Dionyssios
Gallo, Ciro
Pujade-Lauraine, Eric
De Placido, Sabino
Bologna, Alessandra
Weber, Beatrice
Raspagliesi, Francesco
Panici, Pierluigi Benedetti
Cormio, Gennaro
Sorio, Roberto
Cavazzini, Maria Giovanna
Ferrandina, Gabriella
Breda, Enrico
Murgia, Viviana
Sacco, Cosimo
Cinieri, Saverio
Salutari, Vanda
Ricci, Caterina
Pisano, Carmela
Greggi, Stefano
Lauria, Rossella
Lorusso, Domenica
Marchetti, Claudia
Selvaggi, Luigi
Signoriello, Simona
Piccirillo, Maria Carmela
Di Maio, Massimo
Perrone, Francesco
LANCET ONCOLOGY, 2014, 15 (04): : 396 - 405
[48] Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE): a phase 3, multicentre, open-label, randomised trial
Sharman, Jeff P.
Brander, Danielle M.
Mato, Anthony R.
Ghosh, Nilanjan
Schuster, Stephen J.
Kambhampati, Suman
Burke, John M.
Lansigan, Frederick
Schreeder, Marshall T.
Lunin, Scott D.
Zweibach, Alexander
Shtivelband, Mikhail
Travis, Patrick M.
Chandler, Jason C.
Kolibaba, Kathryn S.
Sportelli, Peter
Miskin, Hari P.
Weiss, Michael S.
Flinn, Ian W.
LANCET HAEMATOLOGY, 2021, 8 (04): : E254 - E266
[49] Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial
Ader, Florence
Bouscambert-Duchamp, Maude
Hites, Maya
Peiffer-Smadja, Nathan
Poissy, Julien
Belhadi, Drifa
Diallo, Alpha
Le, Minh-Patrick
Peytavin, Gilles
Staub, Therese
Greil, Richard
Guedj, Jeremie
Paiva, Jose-Artur
Costagliola, Dominique
Yazdanpanah, Yazdan
Burdet, Charles
Mentre, France
LANCET INFECTIOUS DISEASES, 2022, 22 (02): : 209 - 221
[50] Liver transplantation plus chemotherapy versus chemotherapy alone in patients with permanently unresectable colorectal liver metastases (TransMet): results from a multicentre, open-label, prospective, randomised controlled trial
Adam, Rene
Piedvache, Celine
Chiche, Laurence
Adam, Jean Philippe
Salame, Ephrem
Bucur, Petru
Cherqui, Daniel
Scatton, Olivier
Granger, Victoire
Ducreux, Michel
Cillo, Umberto
Cauchy, Francois
Mabrut, Jean-Yves
Verslype, Chris
Coubeau, Laurent
Hardwigsen, Jean
Boleslawski, Emmanuel
Muscari, Fabrice
Jeddou, Heithem
Pezet, Denis
Heyd, Bruno
Lucidi, Valerio
Geboes, Karen
Lerut, Jan
Majno, Pietro
Grimaldi, Lamiae
Levi, Francis
Lewin, Maite
Gelli, Maximiliano
LANCET, 2024, 404 (10458): : 1107 - 1118

← 1 2 3 4 5 →